The results (Figs. 3, 4 and Tables 3, 4) indicated that SHR168442 gave excellent efficacy in both preclinical mouse psoriasis models with favorable PK profile and significant suppression of signature cytokines, IL-17, TNFα and IL-6. Here, IL17A is linked to psoriasis.